Moderna, Inc.'s Q2 2025 earnings highlight a steep revenue decline post-pandemic, with just $0.1bn in revenue and a $(0.8bn) ...

Biotech firm aims to streamline operations and reinvest in high-growth areas such as oncology and rare diseases as it targets ...

Biotechnology company Moderna (NASDAQ:MRNA) announced better-than-expected revenue in Q2 CY2025, but sales fell by 41.1% year ...

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 projected revenue range to $1.5 to $2.2 billion, reflecting a $300 million ...

Despite the limited approval of mNEXSPIKE, the fact that the nod came at all was likely something of a relief for Moderna, given ongoing uncertainties about a potential anti-vaccine agenda at the ...

Q2 2025 Earnings Call Transcript August 1, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-2.13, expectations were $-2.99. Operator: Good day, and thank you for standing by. Welcome ...

Besides Spikevax, the company has secured green lights for its next-generation COVID vaccine, mNEXSPIKE, and the respiratory syncytial virus (RSV) shot mRESVIA.

Moderna also announced FDA approval for mNEXSPIKE® (mRNA-1283), a next-generation vaccine against COVID-19, for use in all adults aged 65 and older, as well as individuals aged 12-64 years with ...